Connect with us

Uncategorized

Mike McCready Talks About Crohn’s And Colitis Foundation

Michael David “Mike” McCready (born April 5, 1966) is an American musician who serves as the lead guitarist for the American rock band Pearl Jam. Along with Jeff Ament, Stone Gossard and Eddie Vedder, he is one of the founding members of Pearl Jam. McCready was also a member of the side project bands Flight to Mars, Temple of the Dog, Mad Season and The Rockfords. He is often regarded as one of the most underrated guitarists of all time.

McCready was inducted into the Rock and Roll Hall of Fame as a member of Pearl Jam on April 7, 2017.

Uncategorized

COVID-19 vaccinations in patients with inflammatory bowel disease

Advances in the treatment of patients with inflammatory bowel disease (IBD) have substantially improved disease activity and quality of life, and reduced hospitalization rates and the need for surgery. However, prolonged immunosuppression in these patients can result in increased susceptibility to opportunistic infections. Many of these infections are preventable through vaccination and immunization strategies that should be undertaken as early as possible after diagnosis because the risk of opportunistic infections increases following the first year of immunosuppressive therapy.

The COVID-19 pandemic has led to substantial concerns for patients with IBD who are on immunosuppressive medications, many of whom are using additional protective measures. Although early COVID-19 studies have suggested that immunosuppressive medications are safe, robust and reproducible data are not available to adequately risk stratify patients with IBD, and current measures are mostly based on observational studies and theoretical risk.

 Large scale, prospective, population-based registry studies, and meta-analyses have identified key risk factors associated with a higher probability of mortality from COVID-19, including age, socioeconomic deprivation, diabetes, respiratory disease, obesity, and being from a Black, Asian, or other minority ethnic group.

One of the best ways to mitigate the risk of COVID-19 is the rapid development of safe and effective vaccines. Although initial phase 1/2 studies are promising,

 patients on immunosuppressant medications have largely been excluded from these studies, creating potential future concerns regarding the safety and generalisability of outcomes for individuals with IBD.

To achieve a sufficient degree of herd immunity, vaccination programs are primarily successful only when there are high rates of coverage and acceptance. The importance of patients with IBD being included in vaccine trials is compounded by the concern that these patients have a lower response to vaccinations and that vaccinations are generally underused in this population. Melmed and colleagues

 showed that in patients with IBD there was an uptake of only 22–46% for the influenza vaccination, and a mere 9% were vaccinated for pneumococcal pneumonia, despite both vaccines being recommended in the British and European IBD guidelines for vaccinating patients.

 A patient survey showed a perceived lack of benefit from a vaccination as the most frequent reason for low vaccine uptake, as well as concerns regarding side-effects, risk of disease flares, needle aversion, and inconvenience.

 However, in the present pandemic, both perception of risk and health awareness might be very different, with implications for vaccine acceptance.

In patients with IBD who were vaccinated against influenza, an immune response was induced, but the use of concomitant infliximab and immunomodulatory therapy were associated with inadequate rates of seroconversion.

 In adult populations vaccinated with the pneumococcal vaccine PSV-23, an impaired immune response was shown in patients with Crohn’s disease taking combination immunosuppressive therapy.

 Other vaccines such as those against hepatitis A and B virus, tetanus, and herpes zoster have also been shown to be potentially less effective in patients with IBD than in control groups.

The extent to which medications might affect vaccine response, independent of underlying disease activity, is unclear. Of note, concurrent anemia, which is a common finding in patients with active IBD, might impair response to vaccinations.

 There is therefore an urgent need for a better understanding of both the effectiveness of potential vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with underlying health conditions, as well as the potential impact of effective disease control on rates of vaccine response.

Currently, the candidate vaccines in phase 3 trials include inactivated, mRNA, or vector-based approaches. The classic inactivated or live-attenuated vaccines raise safety concerns due to possible induction of the disease. However, the ChAdOx1 nCoV-19 trial vaccine uses a replication-deficient chimpanzee adenovirus to deliver a SARS-CoV-2 protein to induce a protective immune response. This vaccine seems to be promising for patients with IBD because adenovirus vectors do not integrate the viral genomic DNA into the host’s genome, are highly immunogenic, and can induce robust innate and adaptive immune responses. The same adenovirus vaccine platform is also being assessed for use against malaria, HIV, influenza, and the Ebola virus.

 Nevertheless, the phase 1/2 trials of the ChAdOx1 nCoV-19 vaccine were done on young, healthy volunteers and as such do not address the potential immunity concerns in patients with chronic diseases or those on immunosuppressants.

 Moreover, we cannot assume that data on one vaccine type in a specific group of people can be extrapolated to other vaccine types.

There needs to be a stronger emphasis on vaccinating patients with IBD within the broader health-care preventative scheme. These factors must be considered when policymakers and national health services start to design and develop future COVID-19 vaccination programs. Equitable access to COVID-19 vaccination programs should be endorsed. If this is not feasible, then we propose that future community vaccination programs support and promote vaccines that can be used by the high-risk cohort of patients with IBD.

Continue Reading

Uncategorized

click here to read more on crohns news

Continue Reading

Uncategorized

stay safe

Having been under virtual house arrest for some time, it’s easy to get carried away with the excitement of a short break, post Covid-19. You’re taking in new sights, sounds, smells and tastes. It’s an adventure for the soul. But rich foods and drinks, lack of exercise and the stress of travel, particularly with young children, can take a toll on your health. To avoid paying for it later on, take a few steps to remain healthy.

REMEMBER TO GET ENOUGH SLEEP

A holiday after such a stressful period for everyone might be much welcomed, but don’t neglect your sleep patterns. Aim for six to nine hours a night and take a short nap in the afternoon if you need it.

WASH YOUR HANDS OFTEN

Stop germs in their tracks. Remember: wet, lather, scrub, rinse, and dry. This isn’t just good advice in a pandemic, it’s important every single day of your life. Practice it frequently throughout the day to prevent spread of diarrhea and respiratory disease, too. PACK SMART While it’s great to finally be free to enjoy a break, beware of the holiday cheer. Many hotels offer complimentary drinks, snacks or cakes. The result can be hard on your system. Pack Udo’s Choice Ultimate Digestive Enzyme Blend, to aid your digestion. A unique blend of seven plant-based digestive enzymes assist in the breakdown of proteins, fats, carbohydrates and fibre. Udo’s Choice Super 8 Microbiotic is a hi-count microbiotic blend that contains eight strains of lacto and bifido bacteria. Each daily capsule contains 42 billion ‘friendly’ bacteria. Both products can be found in your local health food store or pharmacy.

ALWAYS KEEP HYDRATED

Drink lots of water. Spending hours travelling can dehydrate you. Carry a large bottle of water to have throughout your journey, and pack Manuka Lozenges with vitamin C for an added immune boost and try to choose caffeine free drinks throughout the day.

EAT FISH

If you’re staying by the sea, eat lots of fresh grilled fish. Oily fish –including sardines, fresh tuna, salmon and mackerel – is particularly good as it’s rich in Omega 3, which keeps your skin hydrated and encourages healthy digestion as well as weight loss. Try to eat a variety of different coloured fruits and vegetables – oranges, red peppers, green courgettes, yellow sweet corn – to get a wide range of antioxidants.

PROTECT FROM THE SUN

Lying in the sunshine feels great but you only need 10 minutes of unprotected sun to get your daily dose of vitamin D. After that you should use sunblock. As we get older, the collagen in our skin breaks down more rapidly, leading to lines, wrinkles and discolouring. To prevent the breaking down of collagen, eat lots of purple fruits, such as fresh blackberries, blueberries and black grapes.

click here to read more on udos choice supplements

Continue Reading

Most Read